Why attend?
Large pharma: Scouting innovative technologies to discover novel targets, enhance the ability to drug the "undruggable," and more effectively leverage known targets
Biotech: Wanting to understand pharma's targets of interest, validate platform, and extend your cash flow runway
This specialized format and elite attending audience ensures visibility across TPD B2B opportunities and market dynamics.
This summit offers the most efficient use of your partnering conference time:
Engage in direct, face-to-face conversations with dozens of relevant prospective partners
Gain valuable feedback and delve into in-depth discussions with key decision-makers
Cut through the noise of larger, more diverse conferences and effectively differentiate your company and technology
All the while, gain valuable insights into future dealmaking trends and how this dynamic community will drive significant clinical success across the TPD landscape.
Partnering Format
More Targeted
Connect with a targeted critical mass of decision-makers evaluating protein homeostasis assets and discovery platforms. Increase hit rate and efficiency of networking with an entire conference of viable partners, to advance translational efficiency and clinical validation of protein degradation technology.
Earlier Opportunity
Build stronger relationships with key pharma and investor contacts to emphasize your company's competitive edge and understand their targets of interest. Engage face-to-face and have time to schedule follow-up chats without the intensity of a larger crowd.
*The average number of meetings that result in follow-up after the conference is 4.
With Scientific Insights
From expanding the E3 ligase universe to the discovery rationale of molecular glues and the attraction of DACs. Position your company at the front of scientific innovation to show where you add value, as pharma and investors gain strategic insights.
Looking to invest, acquire, license, or partner?
EVENT IN NUMBERS
Laying enabled partnering on top of hyper-relevant scientific discussion so that pharma can contextualize and compare, and biotech can have guaranteed face-to-face meetings with the right, current contacts.
C-level or senior level attendees from over 60 companies
private meeting slots across two days
networking, from candid interactions to pre-scheduled meetings
alignment with all attendees increasing hit-rate and efficiency of networking
Testimonials
The focused niche really increased the impact for us overall. Thanks for including us in the program
David Dowling, Global Search & Evaluation Lead, Pharma Partnering, Roche
It was stellar; I heard this sentiment echoed throughout. We appreciated the focused yet expansive discussions, and talks in a more intimate setting allowing for easier networking, too
Kilang Yanger, Associate Director, Business Development Seach & Evaluation, BMS
I thought it was fantastic - operationally excellent and thoughtfully designed
Albert Hsia, Executive Director, Business Development, Merck
It was a great group of high-quality companies/people in the perfect setting
Melissa Conner, Senior Director of Acquisitions & Licensing, J&J